COMPARATIVE STUDIES OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS CONSUMPTION IN UKRAINE AND SELECTED EUROPEAN COUNTRIES
DOI:
https://doi.org/10.11603/2312-0967.2025.2.15289Keywords:
arterial hypertension, angiotensin-converting enzyme inhibitors, consumption volume, ATC/DDD methodology, pharmaceutical marketAbstract
The aim of the work. To analyze trends in the consumption of angiotensin-converting enzyme inhibitors (ACE inhibitors) in Ukraine during 2021–2023, with a comparison of consumption indicators in the European countries of Estonia and Norway.
Materials and Methods. The study was conducted using data from the State Register of Medicinal Products of Ukraine and the analytical system for pharmaceutical market research "Proxima Research" by the company "Morion." The consumption analysis of the studied drugs was carried out using the ATC/DDD methodology recommended by the WHO. DDDs per 1,000 inhabitants per day (DID) was used as the unit of measurement. Data on ACE inhibitors′ consumption in other European countries were obtained from the respective national registers.
Results and Discussion. It was found that the total consumption of ACE inhibitor monotherapy in Ukraine showed a decreasing trend — from 40.001 DID in 2021 to 36.394 DID in 2023. Among monotherapies, the highest consumption was recorded for enalapril (from 24.58 DID in 2021 to 21.41 DID in 2023), lisinopril (from 6.05 DID to 4.55 DID), and ramipril (from 6.61 DID to 7.41 DID). During the study period, the consumption of combination ACE inhibitors increased by 13.6 %. The highest consumption level was recorded for fixed combination of perindopril with indapamide and amlodipine (18.613 DID in 2023), as well as perindopril with indapamide (13.417 DID in 2023). In the studied European countries, unlike in Ukraine, ramipril ranked first in terms of consumption volume. A high level of consumption of combination drugs (particularly perindopril with amlodipine and indapamide, and perindopril with indapamide) was observed both in Ukraine and in Estonia. Lisinopril consumption in Norway ranked third, accounting for 7.7% of the total drug consumption.
Conclusions. Distinctive features of ACE inhibitor consumption in Ukraine during 2021–2023 were identified. In the structure of ACE inhibitor monotherapy prescriptions in Ukraine, a preference was given to enalapril-based medications, whereas in the European countries studied (Estonia and Norway), ramipril-based drugs were more prevalent. The increased consumption of enalapril in Ukraine is due to its greater economic accessibility for patients, in particular, due to the inclusion of relevant drugs in the Program of State Guarantees of Medical Care for the Population.
References
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957–80.
Alcocer LA, Bryce A, De Padua Brasil D, Lara J, Cortes JM, Quesada D, et al. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines. American Journal of Cardiovascular Drugs. 2023;23:663–82. DOI: 10.1007/s40256-023-00605-5 DOI: https://doi.org/10.1007/s40256-023-00605-5
Mancia G, Kreutz R, Brunström M, et al. The Task Force for the management of arterial hypertension of the European society of hypertension. 2023 ESH guidelines for the management of arterial hypertension. Endorsed by the European renal association (ERA) and the International society of hypertension (ISH). J Hypertens. 2023;41(12):1874–2071. DOI: 10.1097/HJH.0000000000003480 DOI: https://doi.org/10.1097/HJH.0000000000003480
Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284–309. DOI: 10.1097/HJH.0000000000001961 DOI: https://doi.org/10.1097/HJH.0000000000001961
Robocha hrupa z arterialnoi hipertenzii Ukrayinskoi asotsiatsii kardiolohiv. Unifikovanii klinichnyi protokol pervynnoi ta spetsializovanoi medychnoi dopomohy. Hipertonichna khvoroba (arterialna hipertenziia). 2024. 71 s.
Dubrov SO, Kovalenko VM, Vakaluk VM, ta in. Klinichna nastanova, zasnovana na dokazakh "Arterialna hipertenziia". Kyiv: MOZ Ukrainy; 2024. 280 s.
Benenson I. Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers in the Treatment of Hypertension. The Journal for Nurse Practitioners. 2022;18(5):586–7. DOI: 10.1016/j.nurpra.2022.01.027 DOI: https://doi.org/10.1016/j.nurpra.2022.01.027
Zhdan VM, Kitura OYe, Kitura YeM, et al. Arterialna hypertenziia i serceva nedostatnist u zahalnolykarskii praktyci. Simiіna medytsyna. 2020;1–2(87–88):814.
World Health Organization. Hypertension country profile: Estonia, 2023 . Geneva: WHO; 2023. Available from: https://cdn.who.int/media/docs/default-source/country-profiles/hypertension/hypertension-2023/hypertension_est_2023.pdf?download=true&sfvrsn=61086304_4
Mägi K, Lepaste M, Szkultecka-Dębek M. Drug Policy in Estonia. Value in Health Regional Issues. 2018;16:1–4. DOI: 10.1016/j.vhri.2017.10.00. DOI: https://doi.org/10.1016/j.vhri.2017.10.001
World Health Organization. Hypertension country profile: Norway, 2023. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/hypertension-nor-2023-country-profile
Veshnia S. Apteky Norvehiyi – yak pratsiuie farmatsiia krainy f’ordiv? Available from: https://www.rap.in.ua/norske-apotek/.
Derzhavnyy reyestr likarskykh zasobiv Ukrainy. Available from: http://www.drlz.com.ua/
Kompendium. Available from: https://compendium.com.ua/uk/
АТС/DDD Index Tsentru VOOZ z metodolohii statystychnykh doslidzhen LZ. Available from: https://www.whocc.no/atc_ddd_index/
Derzhavnyi formuliar likarskykh zasobiv. Vyp. 30. MOZ Ukrainy, DP "Derzhavnyi ekspertyj centr MOZ Ukrainy". Kyiv; 2021. 1288 s.
Ukraine Population Growth Rate 1950-2025. Available from: https://www.macrotrends.net/global-metrics/countries/UKR/ukraine/population-growth-rate].
Estonian Statistics on Medicines; 2022-2023. Available from: https://ravimiamet.ee/sites/default/files/documents/2024-11/Ravimiamet_aastaraamat_2024.pdf
Drug Consumption in Norway 2019-2023. Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database. Available from: https://www.fhi.no/contentassets/b0802ad9303347b682cf6a8fa701ec91/legemiddelforbruket-i-norge-2019-2023-rapport-2024.pdf
On approval of the Register of medicines and medical devices subject to reimbursement under the program of state guarantees of medical care for the population. Ministry of Health of Ukraine. Order No. 1495, 21.08.2023. Available from: https://zakon.rada.gov.ua/rada/show/v1495282-23#Text.
Sirenko YuM, Torbas OO. Terapiia kombinaciieiu perindoprilu/indapamidu/amlodipinu z tochky zoru onovlenykh rekomendacii i nastanov. Arterialna hipertenziia. 2020;13(1):27-36. DOI: 10.22141/2224-1485.13.1.2020.197886. DOI: https://doi.org/10.22141/2224-1485.13.1.2020.197886
Sleight P. The HOPE study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1(1):18–20. DOI: 10.3317/jraas.2000.002 DOI: https://doi.org/10.3317/jraas.2000.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
Accepted 2025-05-26
Published 2025-06-30
